SCHEMBL14323689

SCHEMBL14323689

O=c1c(OCc2ccccc2)cccn1CCCCc1cn(-c2ccccc2)nn1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 10/20 0.48
▸ DRD3 P35462 10/20 0.48
▸ DRD4 P21917 4/20 0.48
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CYP19A1 P11511 2/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ MIF P14174 2/20 0.40
▸ CD74 P04233 1/20 0.40
▸ HTR1A P08908 3/20 0.40
▸ MPO P05164 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ NOTUM Q6P988 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14324223 0.99 DRD2 (0.49) DRD2DRD3DRD4NPC1RAB9A
SCHEMBL14324505 0.97 DRD2 (0.48) DRD2DRD3DRD4NPC1RAB9A
SCHEMBL14324230 0.80 HDAC8 (0.55) DRD2DRD3DRD4L3MBTL1MIF
SCHEMBL14322139 0.79 HDAC8 (0.54) DRD2DRD3DRD4L3MBTL1MIF
SCHEMBL14323985 0.78 DRD2 (0.54) DRD2DRD3DRD4NPC1L3MBTL1
SCHEMBL3072830 0.77 MAPK14 (0.49) DRD2SMN1; SMN2L3MBTL1BRD4HTR1A
SCHEMBL14323957 0.77 HDAC8 (0.56) DRD2DRD3DRD4NPC1L3MBTL1
SCHEMBL3072834 0.76 MAPK14 (0.51) DRD2SMN1; SMN2L3MBTL1HTR1A
SCHEMBL20382950 0.75 MAPK14 (0.47) DRD2L3MBTL1HTR1A
SCHEMBL3074370 0.75 MAPK14 (0.47) L3MBTL1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871728-B2 Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof GEORGIA TECH RESEARCH CORPORATION (US) 2014-10-28 — — US disclosed
US-20120329741-A1 NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF GEORGIA TECH RESEARCH CORPORATION 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329741-A1 NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF HDAC5, HDAC3, HDAC1 DRD2 3980/4885DRD3 2695/4885DRD4 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback